NPI 1639591423: Open Payments
NPI 1639591423. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$952 in 51 payments from 12 companies in 2025. Trend: 2023 $1,096 · 2024 $1,000 · 2025 $952
Food & beverage: $952
| Company | Payments | Amount |
|---|---|---|
| SCPHARMACEUTICALS INC. | 9 | $181 |
| Merck Sharp & Dohme LLC | 10 | $149 |
| Novartis Pharmaceuticals Corporation | 11 | $136 |
| Medtronic, Inc. | 1 | $101 |
| E.R. Squibb & Sons, L.L.C. | 6 | $94 |
| PFIZER INC. | 5 | $94 |
| Alnylam Pharmaceuticals Inc. | 2 | $59 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $56 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Philips North America LLC | 1 | $20 |
Products named: FUROSCIX, LEQVIO, VERQUVO, SYMPLICITY G3, CAMZYOS, AMVUTTRA, ELIQUIS, Kerendia.
